Loading chart…
CLOSED
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, develops novel therapeutics for central nervous system disorders and unmet needs in mental health in India, the United States, Europe, and internationally. It engages in the development of Masupirdine (SUVN-502), a 5-HT6 receptor antagonist for the treatment of cognitive and neuropsychiatric symptoms of Alzheimer's disease; and Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist/antagonist for the treatment of narcolepsy with or without cataplexy and idiopathic hypersomnia.
Suven Life Sciences Limited (SUVEN) is listed on the NSE in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry. The SUVEN share price is ₹279.50 (+5.53% today), with a market capitalisation of ₹79B. MarketRipple tracks the SUVEN investment thesis, the ripple-chain impact of market events on Suven Life Sciences Limited, and the Healthcare sector outlook.
Open
₹272.00
High
₹293.50
Low
₹269.70
Prev. Close
₹264.85
52W High
₹403.35
52W Low
₹124.11
Day range
₹269.70–₹293.50
52-week range
₹124.11–₹403.35
Volume
839K
P/E
—
ROE
-46.7%
D/E
0.03
Margin
0.0%
Suven Life Sciences Limited (NSE: SUVEN) is currently trading at ₹279.50 (+5.53%).
Suven Life Sciences Limited's market capitalization is ₹79B.
Suven Life Sciences Limited operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic).